DLL3 Therapies Flood Market as Imdeltra Faces Competition

Amgen's Imdeltra (tarlatamab) has gained traction in the first-line setting for small-cell lung cancer, but a rapidly expanding field of DLL3-directed therapies is emerging to challenge its dominance.

The WCLC 2026 conference highlighted several contenders vying for market share, including antibody-drug conjugates and cell therapies. These new entrants aim to capitalize on the growing demand for effective treatments in small-cell lung cancer.

As the field continues to evolve, it remains to be seen which of these DLL3-directed therapies will ultimately prevail as the standard of care.